ProVerum Limited, a medical device company focused on innovative, safe and effective solutions for treating benign prostatic hyperplasia (BPH), today announced it has received FDA approval for its ...

Benign Prostatic Hyperplasia (BPH), or enlarged prostate, is common in men over 50, causing frequent urination and discomfort. While not dangerous, early detection is crucial to prevent complications ...

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...

Benign prostatic hyperplasia (BPH) is one of the most common urologic conditions affecting men as they age, with nearly 50% of men over 50 experiencing symptoms. Despite its prevalence, treatment ...

Discover the innovative minimally invasive surgical techniques (MISTs) reshaping BPH treatment. Learn about benefits, patient ...

Teleflex Incorporated announced the presentation of multiple clinical studies at the 2025 American Urological Association Annual Meeting in Las Vegas, highlighting advancements in treatments for ...

Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...

Source: Getty Images The procedure may be particularly efficacious for men with very large prostates. AMELIA ISLAND, FL—Prostate artery embolization (PAE) has been emerging as a minimally invasive ...

Drug therapy for BPH can be categorized into two groups: agents that interfere with testosterone's stimulatory effect on prostate enlargement and agents that relax prostatic smooth muscle. Of the ...